Dutasteride
- Generic Name
- Dutasteride
- Brand Names
- Avodart, Jalyn
- Drug Type
- Small Molecule
- Chemical Formula
- C27H30F6N2O2
- CAS Number
- 164656-23-9
- Unique Ingredient Identifier
- O0J6XJN02I
- Background
Dutasteride is an oral synthetic 4-azasteroid commonly marketed under the trade name Avodart. It is a novel dual 5α-reductase inhibitor that works by blocking both isoforms of 5α-reductase enzymes in a potent, selective, and irreversible manner. Type I and II 5α-reductase enzymes convert testosterone into dihydrotestosterone (DHT), a primary hormonal mediato...
- Indication
Indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate gland to improve symptoms, and reduce the risk of acute urinary retention and the need for BPH-related surgery alone or in combination with tamsulosin.
- Associated Conditions
- Benign Prostatic Hyperplasia (BPH), Symptomatic benign prostatic hyperplasia (BPH)
- Associated Therapies
- -
JALYN for Benign Prostatic Hyperplasia (BPH) and Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)
- Conditions
- Interventions
- First Posted Date
- 2013-04-12
- Last Posted Date
- 2014-10-22
- Lead Sponsor
- Dr. J. Curtis Nickel
- Target Recruit Count
- 1
- Registration Number
- NCT01830829
- Locations
- 🇨🇦
Centre for Applied Urological Research, Kingston, Ontario, Canada
Dutasteride Treatment for the Reduction of Heavy Drinking in Men
- Conditions
- Interventions
- First Posted Date
- 2013-01-01
- Last Posted Date
- 2019-04-26
- Lead Sponsor
- UConn Health
- Target Recruit Count
- 189
- Registration Number
- NCT01758523
- Locations
- 🇺🇸
University of Connecticut Health Center, Farmington, Connecticut, United States
Bioequivalence - Duodart Against Avodart & Omnic
- Conditions
- Interventions
- First Posted Date
- 2012-08-06
- Last Posted Date
- 2017-06-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 35
- Registration Number
- NCT01657851
- Locations
- 🇷🇺
GSK Investigational Site, Reutov, Moscow Region, Russian Federation
Validation of Digital Morphometry for Cancer Risk in Benign Prostate Biopsies
- First Posted Date
- 2012-05-09
- Last Posted Date
- 2020-10-12
- Lead Sponsor
- University of Illinois at Chicago
- Target Recruit Count
- 139
- Registration Number
- NCT01594502
- Locations
- 🇺🇸
University of Illinois at Chicago, Chicago, Illinois, United States
Study to Compare the Bioavailability of Dutasteride Novel Formulation Form to the Soft Gel Capsule Form in Healthy Male Subjects
- First Posted Date
- 2012-04-16
- Last Posted Date
- 2018-06-19
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 35
- Registration Number
- NCT01577693
- Locations
- 🇺🇸
GSK Investigational Site, Austin, Texas, United States
Study of Enzalutamide (Formerly MDV3100) as a Neoadjuvant Therapy for Patients Undergoing Prostatectomy for Localized Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-03-07
- Last Posted Date
- 2018-10-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 52
- Registration Number
- NCT01547299
Response of Patients on Surveillance for Prostate Cancer to Dutasteride
- First Posted Date
- 2012-02-03
- Last Posted Date
- 2012-02-03
- Lead Sponsor
- Sunnybrook Health Sciences Centre
- Target Recruit Count
- 100
- Registration Number
- NCT01525914
- Locations
- 🇨🇦
Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
Abiraterone Acetate Combined With Dutasteride for Metastatic Castrate Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2011-07-13
- Last Posted Date
- 2018-03-15
- Lead Sponsor
- Mary-Ellen Taplin, MD
- Target Recruit Count
- 40
- Registration Number
- NCT01393730
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Seattle Cancer Care Alliance, Seattle, Washington, United States
🇺🇸University of Washington Medical Center, Seattle, Washington, United States
Drug Use Investigation for AVOLVE(BPH)
- First Posted Date
- 2011-06-20
- Last Posted Date
- 2014-07-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1000
- Registration Number
- NCT01376284
Feasibility of Hormones and Radiation for Intermediate or High Risk Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2011-04-27
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 74
- Registration Number
- NCT01342367
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.